FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Activating mutations in the epidermal growth factor receptor (EGFR) drive lung adenocarcinoma, but responses to EGFR tyrosine kinase inhibitors (TKIs) are variable.
• Tumor cell dependence on mutant EGFR can be modulated by genetic factors, influencing TKI treatment efficacy.

Purpose of the Study:

• To identify genetic modifiers that affect the sensitivity of EGFR-mutant lung cancer cells to EGFR TKIs.
• To investigate the role of the NF-κB pathway in regulating TKI treatment response and resistance.

Main Methods:

• A pooled RNA interference screen was employed to identify genes that enhance TKI-induced cell death.
• NF-κB pathway components were manipulated through genetic (knockdown, overexpression, silencing) and pharmacologic approaches.
• Analysis of patient data correlated IκB expression with TKI treatment response and survival.

Main Results:

• Knockdown of FAS and NF-κB pathway components sensitized EGFR-mutant lung cancer cells to erlotinib.
• Activation of NF-κB conferred resistance to EGFR TKIs, while its inhibition enhanced erlotinib-induced apoptosis.
• Increased IκB expression in patients predicted better response and survival to EGFR TKI therapy.

Conclusions:

• The NF-κB pathway is a key regulator of sensitivity and resistance to EGFR TKIs in lung cancer.
• Inhibiting NF-κB concurrently with EGFR TKIs represents a promising therapeutic strategy for EGFR-mutant lung cancers.
• Understanding NF-κB's role provides insights into mechanisms of oncogene dependence and escape.